MONITOR‐GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy‐induced/febrile neutropenia prophylaxis
Prospective data on the use of granulocyte‐colony‐stimulating factor (G‐CSF) in non‐Hodgkin's lymphoma and its aggressive subtypes, including diffuse large B‐cell lymphoma (DLBCL), are limited. MONITOR‐GCSF is a pan‐European, multicenter, prospective, observational study aiming to describe treatment patterns and clinical outcomes in patients receiving biosimilar filgrastim in the prophylaxis of chemotherapy‐induced neutropenia (CIN) and febrile neutropenia (FN).
No Supplementary Data
No Article Media